EcoR1 Capital Portfolio
13F Holdings & Position Changes — Last filed Feb 17, 2026
13F Holdings & Position Changes — Last filed Feb 17, 2026
EcoR1 Capital is a $5B biotech-focused hedge fund managed by Oleg Nodelman. As of their latest 13F filing (Q4 2025), the fund holds 27 positions worth $2.2B. This quarter they initiated 8 new positions and exited 78. Their largest holding is ZYME ($604.8M).
EcoR1 initiated 8 new positions and increased 3 this quarter. Portfolio grew +5.9% to $2.2B. 256 upcoming catalysts across holdings. 9 insider buys detected in portfolio companies.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
No charge for 14 days · Cancel anytime
EcoR1 Capital held 27 biotech stocks in their 13F portfolio this quarter. Their top positions include ZYME, ANAB, JAZZ, CRNX, CNTA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
EcoR1 Capital's tracked biotech portfolio is worth $2.2B across 27 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
EcoR1 Capital initiated 8 new positions this quarter, including CGON, ZBIO, GPCR, MNKD, EOLS and 3 more. They also increased 3 existing positions.
EcoR1 Capital fully exited 78 positions this quarter, including QURE, RNA, ALKS, MGNX, BCYC and 73 more. They also trimmed 2 existing positions.
Growth-stage crossover fund investing in life sciences companies from late-stage private rounds through public equity. Named after the EcoR1 restriction enzyme, reflecting the firm's scientific roots. Focuses on platform technologies and novel therapeutic modalities.
| $199.6M |
| 5 | CNTA | Increased | 3,115,000 | $77.9M |
| 6 | CRSP | 1,389,276 | $72.9M |
| 7 | MBX | 2,123,604 | $67.0M |
| 8 | IMNM | Decreased | 2,855,590 | $61.3M |
| 9 | ORIC | 6,728,116 | $55.0M |
| 10 | GLPGF | 1,667,119 | $54.5M |
| 11 | XNCR | Decreased | 3,251,112 | $49.8M |
| 12 | BBIO | 2,823,126 | $35.3M |
| 13 | ETON | 2,030,544 | $34.3M |
| 14 | CGON | New | 772,000 | $32.1M |
| 15 | ZBIO | New | 789,500 | $28.7M |
| 16 | NGNE | 1,271,342 | $26.2M |
| 17 | GPCR | New | 334,380 | $23.3M |
| 18 | PCVX | Increased | 450,000 | $20.8M |
| 19 | AQST | 2,625,000 | $17.0M |
| 20 | VYGR | Increased | 4,002,847 | $15.7M |
| 21 | ATRA | 573,183 | $10.4M |
| 22 | MNKD | New | 1,660,000 | $9.4M |
| 23 | NUVB | 963,333 | $8.6M |
| 24 | EOLS | New | 675,000 | $4.5M |
| 25 | IBIO | New | 2,228,000 | $4.3M |
| 26 | MREO | New | 7,856,466 | $3.3M |
| 27 | CAMP | New | 325,000 | $2.0M |
| Q2 2025 |
| $1.7B |
| -0.5% |
| Q1 2025 | $1.7B | -30.9% |
| Q4 2024 | $2.4B | -12.1% |
| Q3 2024 | $2.8B | -7.6% |
| Q2 2024 | $3.0B | -20.3% |
| Q1 2024 | $3.7B | +12.4% |
| Q4 2023 | $3.3B | +30.1% |
| Q3 2023 | $2.6B | -26.4% |
| Q2 2023 | $3.5B | +22.3% |
| Q1 2023 | $2.9B | — |